Takahashi, Shunji

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Burtness, B., Harrington, K. J., Greil, R., Soulières, D., Tahara, M., de Castro, G., Psyrri, A., Basté, N., Neupane, P., Bratland, Å., et al. (2019) · The Lancet

Head and Neck Cancer StudiesCancer Immunotherapy and Biomarkers

Cited by 3,336

Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer

Kobayashi, K., Ito, Y., Matsuura, M., Fukada, I., Horii, R., Takahashi, S., Akiyama, F., Iwase, T., Hozumi, Y., Yasuda, Y., et al. (2016) · Surgery Today

Breast Cancer Treatment StudiesCancer Treatment and Pharmacology

Cited by 45

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors

Takahashi, S., Karayama, M., Takahashi, M., Watanabe, J., Minami, H., Yamamoto, N., Kinoshita, I., Lin, C.-C., Im, Y.-H., Achiwa, I., et al. (2021) · Clinical Cancer Research

HER2/EGFR in Cancer ResearchPharmacogenetics and Drug Metabolism

Cited by 37

Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a Phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma

Pal, S. K., Tannir, N. M., Grell, P., Gao, X., Kotecha, R. R., Picus, J., De Braud, F. G., Takahashi, S., Wong, A., Suárez, C., et al. (2024) · Journal of Clinical Oncology

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 9